A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer

Gray, Heidi

131 - Focused Plenary
A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer

Monday, March 24, 2014: 3:41 PM

Ballroom B/C (Tampa Convention Center)

H. J. Gray¹, M. Cristea², K. M. Bell-McGuinn³, L. P. Martin⁴, M. W. Dudley⁵, W. P. Munasinghe⁵, V. L. Giranda⁵, Y. Luo⁵, M. D. McKee⁵ and G. Fleming⁶
¹University of Washington Medical Centet, Seattle, WA, ²City of Hope, Duarte, CA, ³Memorial Sloan-Kettering Cancer Center, New York, NY, ⁴Fox Chase Cancer Center, Philadelphia, PA, ⁵AbbVie, Inc., North Chicago, IL, ⁶University of Chicago Medical Center, Chicago, IL

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

131 - Focused Plenary
A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer

131 - Focused Plenary A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer

131 - Focused Plenary
A phase I study of veliparib (ABT-888) in combination with carboplatin and gemcitabine in subjects with advanced ovarian cancer